The t(11;14) cancers have a well-defined starting point, with a single, recognizable driver mutation present in all initial cancer cells. Prostate cancer, like many other solid tumors, is more genetically complex (heterogeneity) from the start. However, both cancers evolve as they progress. The key to a durable response lies in the ability to anticipate and manage the genetic heterogeneity that develops over time in response to the drugs used, which leads to drug resistance. I would love to hear about how CureWise addresses evolving genetic mutations in response to treatment, which can cause drug resistance. This is incredibly common with prostate cancer.
Exactly right. Cancer is complex because it never stands still. Precision medicine has to move with it. The challenge is to see the disease as it is today, use the best treatments, and be ready for how it will change tomorrow. Genomic profiling is not a single test, it is a process over time.
The t(11;14) cancers have a well-defined starting point, with a single, recognizable driver mutation present in all initial cancer cells. Prostate cancer, like many other solid tumors, is more genetically complex (heterogeneity) from the start. However, both cancers evolve as they progress. The key to a durable response lies in the ability to anticipate and manage the genetic heterogeneity that develops over time in response to the drugs used, which leads to drug resistance. I would love to hear about how CureWise addresses evolving genetic mutations in response to treatment, which can cause drug resistance. This is incredibly common with prostate cancer.
Exactly right. Cancer is complex because it never stands still. Precision medicine has to move with it. The challenge is to see the disease as it is today, use the best treatments, and be ready for how it will change tomorrow. Genomic profiling is not a single test, it is a process over time.